| Expression pattern: |
DN |
| Associated gene: |
FUS, VEGF-A, AGO2 |
| Associated microRNA: |
miR-93-3p, miR-412-3p, miR-298-5p, miR-7231-3p, miR-6998-3p |
| Biological function: |
enhances angiogenic activity, reduces cardiomyocyte and endothelial cell apoptosis, improves left ventricular function after MI |
| Molecular mechanism: |
circFndc3b binds the RNA-binding protein FUS, reduces FUS levels, and thereby increases VEGF-A expression/signaling; not a miRNA sponge |
| Biological pathway or process: |
angiogenesis (promotes); apoptosis (inhibits); other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RNase R Treatment; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Nuclear-Cytoplasmic Fractionation; Transfection; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; TUNEL; Tube Formation Assay; Transwell Assay; Western Blot; IF (Immunofluorescence); In Vivo Animal Model; H&E Staining |
| Clinical significance: |
significantly reduced in LV tissues of ischemic cardiomyopathy patients compared to non-failing hearts; may have clinical significance in MI pathophysiology |
| Description: |
circFndc3b is down-regulated after MI (mouse hearts) and in ischemic cardiomyopathy (human LV). Restoring circFndc3b expression protects the post-MI heart by reducing apoptosis and promoting neovascularization, largely through binding the RBP FUS and increasing VEGF-A signaling rather than via miRNA sponging. |
| Confidence score: |
0.7768 |